6 Best Peptides for Gastroparesis

What to Know Before Choosing a Peptide for Gastroparesis

Gastroparesis is a condition where the stomach empties too slowly, not because of a physical blockage, but because the signals and cells that drive normal stomach movement have been damaged or lost. Symptoms range from persistent nausea and vomiting to early fullness, bloating, and significant weight loss. The only FDA-approved medication in the United States is metoclopramide, and its use is restricted to short-term treatment because of serious neurological risks with prolonged administration. That gap in the standard-of-care landscape is a large part of why people look at research-grade peptides.

Every peptide in this guide earned its place under one criterion: people use it or are actively discussing using it for gastroparesis. That includes compounds at every point on the regulatory spectrum, from investigational drugs in clinical trials to research chemicals with no approval anywhere. Evidence strength is stated honestly inside each entry, but it is never the filter for inclusion. A compound with only animal studies or community-reported use still belongs here, with its thin evidence named plainly. A reader who already knows this space will notice quickly if a well-discussed compound is missing.

One important distinction before reading further: GLP-1 receptor agonists such as semaglutide and tirzepatide are peptide-based drugs, but they are a recognized cause of delayed gastric emptying, not a treatment for it. They slow the stomach intentionally as part of how they work for blood sugar control and weight loss, which can tip vulnerable individuals into full gastroparesis. Motility specialists routinely advise their gastroparesis patients against starting GLP-1 agonists. This guide focuses on the peptides people use in pursuit of relief from gastroparesis.

The compounds below are numbered by how prominently each appears in published research and documented real-world use for this goal. That order is a spine for the list, not a verdict from best to worst, and it is not a recommendation of one compound over another. The right choice for any individual depends on their specific situation, medical history, and what they work out with clinical guidance.

1. Relamorelin: The Most Clinically Advanced Peptide for Diabetic Gastroparesis

Relamorelin, also called RM-131, is a synthetic ghrelin receptor agonist. Ghrelin is a hormone the body produces naturally to stimulate hunger and gastric motility. Relamorelin mimics that signal by binding to the same receptor, called the growth hormone secretagogue receptor or GHSR-1a. When that receptor is activated, it drives coordinated contractions in the stomach body and antrum, the muscular zone responsible for grinding food and pushing it toward the small intestine. The result is an accelerated gastric emptying rate through a mechanism entirely distinct from metoclopramide's dopamine-blocking approach.

No peptide in this space has more rigorous human data behind it for gastroparesis. Relamorelin has completed two placebo-controlled Phase 2 clinical trials in people with diabetic gastroparesis who had active vomiting as a primary symptom, and both studies produced statistically meaningful reductions in vomiting and improvements in gastric emptying rate. It is the only ghrelin agonist to advance to Phase 3 trials for this indication, and a systematic review and meta-analysis of ghrelin agonists in diabetic gastroparesis has been published, further anchoring its position as the lead clinical candidate in the peptide space for this condition.

Two limitations are worth stating clearly. First, the evidence base is specific to diabetic gastroparesis with active vomiting. Relamorelin's efficacy has not been established for idiopathic gastroparesis, which has a different pathological profile and a different patient population. Second, relamorelin is investigational only. It is not FDA-approved, not available through a pharmacy, and not accessible through telehealth channels as of 2026. Its relevance here is as the compound that best validates the ghrelin-agonist mechanism in a controlled human setting and as the clinical benchmark against which other peptides in this space should be measured.

Like standard prokinetic drugs, relamorelin stimulates gastric contractions without addressing the underlying cellular damage that drives gastroparesis, specifically the loss of the stomach's electrical pacemaker cells and the degeneration of nitric oxide-producing neurons in the enteric nervous system. That distinction matters when comparing it to some of the compounds further down this list.

2. BPC-157: For Vagal and Enteric Nervous System Repair

BPC-157, or Body Protection Compound-157, is a 15-amino-acid peptide derived from a sequence found in human gastric juice protein. It is a research-grade compound with no FDA approval and no clinical indication, supplied as a research chemical. Among the peptides discussed and used in functional medicine and self-directed health communities for gut conditions, BPC-157 is the most widely mentioned, and for gastroparesis specifically it generates more active community interest than any other research peptide.

The reason for that interest comes down to mechanism. BPC-157 operates through two pathways that are both relevant to the root-cause pathology of gastroparesis. The first is vagal activation: preclinical research shows BPC-157 stimulates the vagus nerve, which triggers the cholinergic anti-inflammatory pathway, a signaling chain that suppresses macrophage and T-cell infiltration in the gastric muscularis. That inflammatory infiltration is a primary driver of damage to the stomach's electrical pacemaker cells. Blocking the vagus nerve in preclinical models eliminates the majority of BPC-157's effect on gastric motility restoration, which confirms that the vagal pathway is central rather than incidental to how it works. The second pathway is direct modulation of neuronal nitric oxide synthase neurons in the enteric nervous system. Those neurons produce nitric oxide, a signal that allows the pylorus, the valve between the stomach and small intestine, to relax. In gastroparesis, that relaxation is impaired partly because these neurons have degenerated. Preclinical work shows that blocking nitric oxide synthesis blunts roughly half of BPC-157's motility effect, confirming a pathway independent of the vagal route.

Those two mechanisms together explain why gastroparesis communities have focused on BPC-157 specifically: it targets the neural and inflammatory processes that cause gastroparesis rather than simply forcing the stomach to contract harder. On gastroparesis forums, users discuss it primarily in the context of vagus nerve healing and the possibility that repairing vagal function could restore motility over time. That framing is speculative, but it is mechanistically coherent given what the preclinical research shows.

The honest caveat is significant: no large-scale human clinical trial has been published for BPC-157 in gastroparesis as of 2026. The evidence is preclinical and animal-derived, alongside anecdotal community reporting. The mechanistic story is compelling, but it has not been confirmed in controlled human data. People use it and discuss it seriously, which is why it belongs on this list. Anyone considering it is working from preclinical evidence and peer experience rather than clinical trial confirmation.

3. KPV: For the Inflammatory Component of Gastroparesis

KPV is a tripeptide made up of lysine, proline, and valine. It is derived from the C-terminal end of alpha-melanocyte stimulating hormone, a naturally occurring peptide with well-characterized anti-inflammatory properties. KPV carries those anti-inflammatory properties in a smaller, more targeted form, acting on melanocortin receptors in the gastrointestinal tract to reduce pro-inflammatory cytokine signaling and decrease inflammatory cell infiltration in the gut wall.

Its relevance to gastroparesis comes from the condition's underlying pathology. The stomach's interstitial cells of Cajal, which function as electrical pacemakers for gastric contractions, are vulnerable to oxidative stress and inflammatory damage. The same inflammatory environment, driven by macrophage and T-cell activity in the gastric muscularis, also accelerates the degeneration of the nitric oxide-producing neurons in the enteric nervous system. Reducing that inflammation does not directly stimulate gastric emptying, but it may protect the cellular structures that make normal motility possible in the first place.

KPV is most often used in combination with BPC-157 rather than as a standalone approach. The pairing appears frequently in functional medicine contexts, sometimes in a combined formulation, because BPC-157 targets the vagal and neural motility pathways while KPV targets the inflammatory pathways, and the two mechanisms address complementary aspects of the condition's underlying damage. Community reporting on KPV as a standalone compound for gastroparesis is sparse; most of the discussion involves it as part of a combination approach.

No dedicated clinical trial data has been published for KPV in gastroparesis. Its anti-inflammatory properties are supported by published research on alpha-MSH derivatives, but the application to gastroparesis relies on mechanistic reasoning about inflammatory contributions to motility failure, not on clinical outcome data. KPV earns its place here because people use it for this goal in combination protocols, not because a clinical trial confirmed it works for gastroparesis specifically.

4. GHK-Cu: For Protecting the Stomach's Pacemaker Cells

GHK-Cu is a tripeptide-copper complex consisting of glycine, histidine, and lysine bound to a copper ion. It is a naturally occurring compound found in human plasma and has been studied in research contexts for its effects on tissue repair, antioxidant biology, and cell signaling. In the gastroparesis research space, it is discussed as a candidate based on a specific and mechanistically grounded rationale: protecting interstitial cells of Cajal from oxidative damage.

ICCs, as those pacemaker cells are called, generate the slow electrical waves that coordinate the contractions moving food through the digestive tract. In gastroparesis, ICC populations are reduced, particularly the Kit-positive subtype, and that loss directly impairs gastric emptying. The damage is driven substantially by oxidative stress in the gastric environment. GHK-Cu activates the Nrf2 transcription factor, which functions as a master switch for the body's endogenous antioxidant defenses, upregulating protective enzymes in cells under oxidative stress. It also modulates the SCF-Kit signaling pathway, which governs ICC survival and function. Together, those actions point toward a role in preserving pacemaker cells rather than directly stimulating contractions.

No human clinical trial data has been published for GHK-Cu in gastroparesis as of 2026. Its candidacy for this list is based on preclinical and mechanistic research, along with its presence in discussions among researchers and practitioners investigating root-cause approaches to gastroparesis. It does not generate the same volume of community discussion as BPC-157, and it is not widely used in self-directed protocols for this condition. It belongs here because its mechanism is specific and directly relevant to a core pathological process in gastroparesis, and because researchers exploring ICC-targeted approaches have begun naming it in this context.

5. MOTS-c: For Metabolic Stress and ENS Neuron Protection in Diabetic Gastroparesis

MOTS-c is a peptide encoded in the mitochondrial genome rather than the nuclear genome, which makes it unusual among the compounds in this guide. It plays a role in cellular energy regulation and the response to metabolic stress. Its relevance to gastroparesis is specific to the diabetic subtype and to the mechanism by which that subtype damages the enteric nervous system.

In diabetic gastroparesis, sustained high blood glucose creates chronic metabolic stress on the neurons of the enteric nervous system, particularly the nNOS neurons that produce nitric oxide for pyloric relaxation. That energetic stress drives mitochondrial dysfunction in those neurons, leading to their degeneration and the loss of nitric oxide signaling that follows. MOTS-c addresses that cascade by activating AMPK, an enzyme that functions as a cellular energy sensor and shifts cells into an energy-preserving state, and by stimulating PGC-1 alpha, a key regulator of mitochondrial biogenesis. Think of it as a recovery program for neurons whose power plants are failing under metabolic stress. Those effects restore mitochondrial function in stressed ENS neurons, which preserves nNOS expression and helps maintain the nitric oxide signaling that gastroparesis patients have lost.

No human clinical trial data has been published for MOTS-c in gastroparesis. The mechanistic case is preclinical and is most relevant to diabetic gastroparesis rather than the idiopathic form, because the mechanism centers on metabolic stress from hyperglycemia rather than a general inflammatory or structural process. Community reporting on its use for gastroparesis is sparse. It belongs here because the mechanism addresses a well-characterized pathological process in diabetic gastroparesis at the cellular level and because it appears in research and practitioner discussions about ENS-targeted approaches to the condition.

6. Native Ghrelin: The Proof-of-Concept Peptide for the Ghrelin Pathway

Native ghrelin is the naturally occurring peptide hormone the body produces to signal hunger and stimulate gastric motility. It acts on the same GHSR-1a receptor that relamorelin targets, and it has been studied in pilot settings to establish whether the ghrelin pathway itself is a valid target in human gastroparesis, independent of any synthetic agonist.

In small pilot studies, acute intravenous ghrelin enhanced gastric emptying rate in both idiopathic and diabetic gastroparesis. That finding matters because it provides human proof-of-concept for the ghrelin mechanism across both subtypes of the condition, not just the diabetic form that relamorelin's Phase 2 data covers. The caveat is that native ghrelin is not a practical treatment option. It has a short half-life in circulation, requires intravenous administration, and no ongoing therapy using intravenous ghrelin for gastroparesis has been developed. Its role in the research landscape is to confirm that activating the ghrelin receptor accelerates gastric emptying in humans with gastroparesis, which is the scientific foundation that justified relamorelin's development and informs ongoing work on ghrelin agonists as a drug class.

No ghrelin-based product is available for clinical or research use for gastroparesis as of 2026. Native ghrelin is on this list because the pilot data represents genuine human evidence for a relevant mechanism, and because understanding its role clarifies why the research community has invested in synthetic ghrelin agonists for this indication.

How These Peptides Compare

Frequently Asked Questions

Are any of these peptides FDA-approved for gastroparesis?

None of the research-grade peptides in this guide are FDA-approved for any indication. Relamorelin is the furthest along in clinical development and has reached Phase 3 trials, but it remains investigational and unavailable for clinical use. The only FDA-approved medication for gastroparesis in the United States is metoclopramide, and its use is restricted because of neurological risks with long-term administration.

How is BPC-157 different from standard prokinetic drugs for gastroparesis?

Standard prokinetics like metoclopramide work by blocking dopamine receptors or activating serotonin receptors to force stronger stomach contractions. BPC-157 works through a different set of pathways entirely: activating the vagus nerve to reduce inflammation in the gastric wall and supporting the nitric oxide-producing neurons that allow the pylorus to relax. In preclinical models, that distinction means BPC-157 targets some of the cellular damage driving gastroparesis rather than simply overriding a malfunctioning system with a stronger signal. No human clinical trial has yet confirmed whether that preclinical distinction translates to better or more durable outcomes in people.

Can peptides be used alongside standard gastroparesis treatments?

This is a question that belongs with a physician familiar with gastroparesis and with the specific compounds under consideration. Some of the compounds in this guide, particularly BPC-157 and KPV, appear in functional medicine contexts alongside conventional care rather than as replacements for it. No combination protocol has been studied in a controlled clinical setting for gastroparesis, and interaction data for most of these compounds in human use does not exist. Clinical oversight is essential before adding any research-grade peptide to an existing treatment regimen.

What is the difference between ghrelin agonists and root-cause peptides for gastroparesis?

Ghrelin agonists like relamorelin and native ghrelin stimulate gastric contractions by activating a receptor that drives the stomach to move food forward. They work around the underlying damage rather than addressing it directly. Root-cause candidates like BPC-157, GHK-Cu, and MOTS-c target the cellular processes behind that damage: the loss of pacemaker cells, the degeneration of nitric oxide-producing neurons, and the inflammatory and metabolic stress environments that cause those losses. In theory, root-cause approaches could produce more durable improvements if the underlying damage is reversible, but no human trial has tested that hypothesis yet.

Why do GLP-1 agonists keep coming up in gastroparesis discussions if they cause the condition?

GLP-1 receptor agonists intentionally slow gastric emptying as part of how they work for blood sugar control and weight loss. For people without gastroparesis, that slowdown is usually manageable. For people who already have impaired gastric motility, or who are predisposed to it, GLP-1 agonists can tip the stomach into full gastroparesis. Motility specialists routinely advise gastroparesis patients against starting these drugs, and people who develop gastroparesis while on a GLP-1 agonist are generally advised to discontinue it. They appear in this discussion not as a treatment option but as a recognized cause that anyone searching this topic needs to understand clearly.

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and documented real-world use of peptides for gastroparesis in one place.